Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19093883rdf:typepubmed:Citationlld:pubmed
pubmed-article:19093883lifeskim:mentionsumls-concept:C0376622lld:lifeskim
pubmed-article:19093883lifeskim:mentionsumls-concept:C1704939lld:lifeskim
pubmed-article:19093883lifeskim:mentionsumls-concept:C0012373lld:lifeskim
pubmed-article:19093883lifeskim:mentionsumls-concept:C0021467lld:lifeskim
pubmed-article:19093883lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:19093883lifeskim:mentionsumls-concept:C1823242lld:lifeskim
pubmed-article:19093883lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:19093883lifeskim:mentionsumls-concept:C0456387lld:lifeskim
pubmed-article:19093883lifeskim:mentionsumls-concept:C1533691lld:lifeskim
pubmed-article:19093883lifeskim:mentionsumls-concept:C0243071lld:lifeskim
pubmed-article:19093883lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:19093883lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:19093883pubmed:issue2lld:pubmed
pubmed-article:19093883pubmed:dateCreated2009-1-15lld:pubmed
pubmed-article:19093883pubmed:abstractTextThe reversal of multidrug resistance by 22 molecules [8-aryl-8-hydroxy-5-R'-8H-[1,4]thiazino[3,4-c][1,2,4]oxadiazol-3-ones (1a-i) and 8-aryl-8-alkoxy-5-methyl-8H-[1,4]thiazino[3,4-c][1,2,4]oxadiazol-3-ones (2a-m)] related to myocardial-calcium-channel-modulator diltiazem was studied in multidrug resistant A2780/DX3 and their sensitive counterpart A2780 cells. MTT, cytofluorimetry assays, and fluorescence microscopy analyses were used to define activity and accumulation of doxorubicin with or without the diltiazem-like modulators. Of the 22 molecules, 1a, 2f, 2g, and 2m were able to overcome the established criteria for the selection in A2780/DX3 cells (IC(50) reduction > or = 25%), but only 2f, 2g, and 2m caused a significant increase of intracellular accumulation of doxorubicin. In conclusion, experiments lead to the identification of three diltiazem-like molecules able to increase the intracellular accumulation of doxorubicin by inhibiting the MDR1 function, thus potentiating its antiproliferative activity in multidrug resistant A2780/DX3 cells.lld:pubmed
pubmed-article:19093883pubmed:languageenglld:pubmed
pubmed-article:19093883pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19093883pubmed:citationSubsetIMlld:pubmed
pubmed-article:19093883pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19093883pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19093883pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19093883pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19093883pubmed:statusMEDLINElld:pubmed
pubmed-article:19093883pubmed:monthJanlld:pubmed
pubmed-article:19093883pubmed:issn1520-4804lld:pubmed
pubmed-article:19093883pubmed:authorpubmed-author:CianfrigliaMa...lld:pubmed
pubmed-article:19093883pubmed:authorpubmed-author:SpinelliDomen...lld:pubmed
pubmed-article:19093883pubmed:authorpubmed-author:VialeMaurizio...lld:pubmed
pubmed-article:19093883pubmed:authorpubmed-author:CastagnolaPat...lld:pubmed
pubmed-article:19093883pubmed:authorpubmed-author:CosimelliBarb...lld:pubmed
pubmed-article:19093883pubmed:authorpubmed-author:PetrilloGiova...lld:pubmed
pubmed-article:19093883pubmed:authorpubmed-author:de...lld:pubmed
pubmed-article:19093883pubmed:authorpubmed-author:AielloCinziaClld:pubmed
pubmed-article:19093883pubmed:authorpubmed-author:CordazzoCinzi...lld:pubmed
pubmed-article:19093883pubmed:authorpubmed-author:SeveriEldaElld:pubmed
pubmed-article:19093883pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19093883pubmed:day22lld:pubmed
pubmed-article:19093883pubmed:volume52lld:pubmed
pubmed-article:19093883pubmed:ownerNLMlld:pubmed
pubmed-article:19093883pubmed:authorsCompleteYlld:pubmed
pubmed-article:19093883pubmed:pagination259-66lld:pubmed
pubmed-article:19093883pubmed:meshHeadingpubmed-meshheading:19093883...lld:pubmed
pubmed-article:19093883pubmed:meshHeadingpubmed-meshheading:19093883...lld:pubmed
pubmed-article:19093883pubmed:meshHeadingpubmed-meshheading:19093883...lld:pubmed
pubmed-article:19093883pubmed:meshHeadingpubmed-meshheading:19093883...lld:pubmed
pubmed-article:19093883pubmed:meshHeadingpubmed-meshheading:19093883...lld:pubmed
pubmed-article:19093883pubmed:meshHeadingpubmed-meshheading:19093883...lld:pubmed
pubmed-article:19093883pubmed:meshHeadingpubmed-meshheading:19093883...lld:pubmed
pubmed-article:19093883pubmed:meshHeadingpubmed-meshheading:19093883...lld:pubmed
pubmed-article:19093883pubmed:meshHeadingpubmed-meshheading:19093883...lld:pubmed
pubmed-article:19093883pubmed:meshHeadingpubmed-meshheading:19093883...lld:pubmed
pubmed-article:19093883pubmed:meshHeadingpubmed-meshheading:19093883...lld:pubmed
pubmed-article:19093883pubmed:year2009lld:pubmed
pubmed-article:19093883pubmed:articleTitleInhibition of MDR1 activity in vitro by a novel class of diltiazem analogues: toward new candidates.lld:pubmed
pubmed-article:19093883pubmed:affiliationIstituto Nazionale per la Ricerca sul Cancro, S.C. Terapia Immunologica, L.go R. Benzi 10, 16132 Genova, Italy.lld:pubmed
pubmed-article:19093883pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19093883pubmed:publicationTypeIn Vitrolld:pubmed
pubmed-article:19093883pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:19093883lld:chembl